Slideshow
Agents that target the TH17-interleukin pathway show promise in psoriatic arthritis, as alternatives for patients who don't benefit from TNFα blockers. This slide show describes their mode of action and potential.
CASPAR Criteria May Identify More Patients With Juvenile PsA Than ILAR Criteria
Emerging Agents in the Treatment of Rheumatic Diseases
FDA Accepts New Drug Application for TNX-102 SL in Fibromyalgia
Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis
Women Who Give Birth After Infertility Have Elevated Risk of Systemic Rheumatic Disease
Patient Education Materials for Rheumatology, Internal Medicine Don’t Meet Readability Standards